Fact Meets Function

Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats.

This study examined the effects of Dihexa, an angiotensin IV analog, on rat models of Huntington’s disease induced by 3-nitropropionic acid exposure. Researchers found that Dihexa treatment reduced motor deficits and protected against neuronal damage in treated animals compared to controls. **Evidence level: Animal model** (Note: The source designation of “Human Clinical” appears inconsistent with the study design, which used rat models rather than human subjects).

Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats. Read Post »

Behavioral and neuropathological features of Alzheimer’s disease are attenuated in 5xFAD mice treated with intranasal GHK peptide.

This study examined intranasal GHK peptide treatment in 5xFAD transgenic mice, a model of Alzheimer’s disease, and found that treatment attenuated both behavioral deficits and neuropathological features including amyloid-beta accumulation and neuroinflammation (animal model). The research demonstrates potential mechanisms by which GHK peptide may modulate disease-relevant pathways in Alzheimer’s disease progression, though findings are limited to preclinical mouse studies that do not directly translate to human outcomes (evidence level: animal model).

Behavioral and neuropathological features of Alzheimer’s disease are attenuated in 5xFAD mice treated with intranasal GHK peptide. Read Post »

Effects of Gly-His-Lys-D-Ala Peptide on Skin Wound Regeneration Processes.

This animal model study investigated how the Gly-His-Lys-D-Ala (GHK) peptide affects skin wound healing processes. The research examined the peptide’s effects on various biological mechanisms involved in wound regeneration in animal subjects. This is animal model-level evidence and does not establish direct applicability to human wound care.

Effects of Gly-His-Lys-D-Ala Peptide on Skin Wound Regeneration Processes. Read Post »

Behavioral and neuropathological features of Alzheimer’s disease are attenuated in 5xFAD mice treated with intranasal GHK peptide.

This animal model study investigated whether intranasal administration of GHK peptide could reduce Alzheimer’s disease-related symptoms in 5xFAD transgenic mice, which exhibit amyloid pathology and cognitive decline. The researchers found that GHK peptide treatment attenuated both behavioral deficits and neuropathological features associated with Alzheimer’s disease in these mice. This is an animal model study and represents preclinical evidence that would require human clinical validation before any therapeutic applications could be considered.

Behavioral and neuropathological features of Alzheimer’s disease are attenuated in 5xFAD mice treated with intranasal GHK peptide. Read Post »

Intranasal GHK peptide enhances resilience to cognitive decline in aging mice.

Research Summary

Researchers administered the GHK peptide intranasally to aging mice and assessed its effects on cognitive function and resilience to decline. The study found that intranasal GHK peptide treatment was associated with enhanced cognitive resilience and reduced cognitive decline in the aging mouse model. This is an **animal model study** with potential relevance to understanding peptide-based approaches in aging, though findings require validation in human populations before clinical application.

Intranasal GHK peptide enhances resilience to cognitive decline in aging mice. Read Post »

Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats.

This animal model study investigated the effects of BPC 157, a synthetic gastric pentadecapeptide, on tissue reperfusion outcomes in rats subjected to maintained intra-abdominal hypertension (Grade III and IV). The researchers found that BPC 157 administration improved reperfusion parameters and reduced tissue damage following the hypertensive insult compared to control animals. **Evidence level: Animal model** (Note: The source metadata indicates “Human Clinical,” but the study design and methods described are rat-based research, making this an animal model study rather than human clinical evidence.)

Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats. Read Post »

Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application.

Researchers investigated liposomes as delivery vehicles for GHK-Cu tripeptide to improve its cosmetic application potential through in vitro studies. The research evaluated how liposome formulations could enhance the stability and penetration of GHK-Cu, a copper-containing peptide used in skincare products. This was an in vitro study examining formulation properties rather than human or animal testing.

Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application. Read Post »

Exploring Methylene Blue and Its Derivatives in Alzheimer’s Treatment: A Comprehensive Review of Randomized Control Trials.

This review article examined randomized controlled trials investigating methylene blue and its derivatives as potential treatments for Alzheimer’s disease, synthesizing evidence from human clinical trials. The review identified that methylene blue demonstrates some cognitive benefits in Alzheimer’s patients, though results across trials showed variable efficacy and the optimal dosing and formulation remain unclear. Evidence level: Human clinical trials (via systematic review).

Exploring Methylene Blue and Its Derivatives in Alzheimer’s Treatment: A Comprehensive Review of Randomized Control Trials. Read Post »

Relief of ovalbumin-induced airway remodeling by the glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex via activation of SIRT1 in airway epithelial cells.

This in vitro and animal model study investigated how a glycyl-L-histidyl-L-lysine-copper (GHK-Cu) tripeptide complex affects airway remodeling in ovalbumin-sensitized mice by activating the SIRT1 pathway in airway epithelial cells. The researchers found that GHK-Cu treatment reduced airway remodeling markers, including decreased collagen deposition and smooth muscle thickening, through SIRT1 activation in epithelial cells. The evidence level is animal model and in vitro research, not human clinical evidence.

Relief of ovalbumin-induced airway remodeling by the glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex via activation of SIRT1 in airway epithelial cells. Read Post »

The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials.

This review article examines the melanocortin system’s role in inflammatory bowel disease (IBD) pathogenesis, exploring how melanocortin receptors and their peptide ligands—including the tripeptide KPV—modulate intestinal inflammation through immune cell regulation and barrier function (review of human clinical, animal model, and in vitro evidence). The authors discuss mechanisms by which melanocortin signaling reduces pro-inflammatory cytokine production and promotes mucosal healing, alongside current understanding of therapeutic applications in IBD management. The evidence level is mixed, synthesizing findings from human clinical studies, animal models, and in vitro experiments to characterize the melanocortin system’s therapeutic potential.

The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials. Read Post »

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.

Researchers investigated whether SLU-PP-332, a synthetic agonist targeting estrogen-related receptors (ERRα/β/γ), could induce exercise-like metabolic responses in humans. The study found that SLU-PP-332 activated ERRα-dependent pathways that mimicked acute aerobic exercise responses and improved exercise capacity in human subjects. This is human clinical evidence demonstrating pharmacological activation of metabolic pathways associated with exercise adaptation.

Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. Read Post »

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.

This randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation across multiple centers in healthy middle-aged adults using dose-dependent treatment groups. The study assessed both safety outcomes and efficacy measures, with findings specific to how NMN supplementation affected the study population at varying doses. This evidence represents a human clinical trial, the highest level of evidence for establishing effects in human populations.

The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Read Post »

Scroll to Top